Base to Base Biotech

This week, we have a conversation with Peter G. Milner, founder and director of Renexxion, about GI motility disorders.

Renexxion

Renexxion, Inc. is a privately held US-headquartered clinical-stage biopharmaceutical company, with a subsidiary in Ireland, committed to developing new therapies for patients with gastrointestinal disorders.

Renexxion’s lead program is naronapride, a late-stage drug candidate being developed for mult...

Times:

01:33 Cyllene Tx

21:37 LinusBio

This week, we have conversations with LinusBio founder and Mt. Sinai environmental professor, Dr. Manish Arora, as well as with Philippe Chambon, CEO of Cyllene Therapeutics (Cyllene Tx).

Cyllene Therapeutics

Cyllene Therapeutics is a global leader in non-replicating HSV-1 (nrHSV-1) vector technology in neurology. It is currently executing a phase 1/2 study in the US with its lead DNA medicine cand...

This week, we have a conversation with Kyle Cordova, founder and CEO of AquaPoro.

AquaPoro

AquaPoro is a deeptech company engineering systems that can harvest water from the atmosphere based in California that was spun out of Jordan's Royal Scientific Society.

Atmospheric water generators (AWGs) aren't uncommon as freshwater becomes scarcer for use in a variety of industries from food and beverages to pharmaceutical companies.

AquaPor...

Times:

02:58 Deep Science Ventures

22:16 4basebio

This week, we have a conversation with Amy Walker, CEO of 4basebio, and Adam Tomassi-Russell, senior director, climate, at Deep Science Ventures.

4basebio

4basebio is a UK-based biotechnology company pioneering the use of synthetic DNA to enable next-generation therapeutics and vaccines.

Through its proprietary enzymatic DNA synthesis platform, 4basebio produces GMP-grade synthetic DNA an...

This week, we have a conversation with Jeff Fischer, president of Longhorn Vaccines & Diagnostics, and with Hannah Amies, founder and CEO of Luvida.

Times:

03:03 Longhorn Vaccines and Diagnostics

25:03 Luvida

Longhorn Vaccines & Diagnostics on breakthroughs in molecular testing

Maryland-based Longhorn Vaccines and Diagnostics is a IND-enabling stage biopharmaceutical company developing vaccines, monoclonal antibodies, and diagno...

This week, we have a conversation with Houdini Bio CEO and co-founder Jonathan Cohen-Gold.

Houdini Bio has announced its official launch, having raised approximately £1.5m in non-dilutive grant funding and capital from an oversubscribed pre-seed round.

The funding enables Houdini Bio to validate its technology and achieve projected technical milestones in a third of the predicted time. The platform- a machine learning-guided DNA sequ...

This week on Base to Base, we have a conversation with Bora Pharmaceuticals’ chief commercial officer Jean-Baptiste (JB) Agnus.

Bora Pharmaceuticals

Bora Pharmaceuticals is an international contract development and manufacturing organization (CDMO) specialising in formulation development, clinical and commercial manufacturing, and packaging of complex oral solid dose, liquid, semi-solid, biologics, and sterile injectable pharma...

This week, we have a conversation with Mark Sawicki, president and CEO of Cryoport Systems, and we chat with Nick Manusos, CEO of Kenai Therapeutics.

Times:

03:22 Cryoport Systems

22:24 Kenai Therapeutics

Cryoport Systems

Cryoport Systems provides temperature-controlled supply chain solutions for the life sciences industry. The company supports the transportation, storage and management of sensitive biological materials used in biopharm...

This week, we have a conversation with Revalesio president Greg Archambeau about tackling strokes, and other conditions, with a novel method.

Revalesio

While the pharmaceutical industry often focuses on complex chemical compounds, Revalesio is pioneering a novel drug class rooted in a surprising field: fluid physics.

Revalesio is also focusing on stroke, a condition in need of new therapies.

Revalesio’s breakthrough therapy, RNS6...

This week, we speak with John Friend, CEO of Kazia Therapeutics; and have a conversation with PureTech Health CEO Robert Lyne and Eric Elenko, president and co-founder of PureTech and acting CEO of Gallop Oncology.

Times:

03:23 Kazia Therapeutics

31:56 PureTech Health

PureTech Health

PureTech Health plc is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value.

The company recen...

This week, we have a conversation with the founder, director and chief scientific advisor of Alessa Therapeutics, Pamela Munster.

Alessa Therapeutics

Alessa Therapeutics recently announced positive preliminary phase 1 safety and efficacy data for its prostate cancer treatment Enolen.

This was the first study to demonstrate that the FDA-approved prostate cancer compound enzalutamide can be safely and locally administered to the prostat...

This week, we have a conversation with DIA chief science and regulatory officer, Maria Vassileva, and Medicus Pharma CEO, Raza Bokhari.

Times:

02:53 Medicus Pharma

29:13 DIA

DIA

DIA (Drug Information Association) is a global organisation that assists life science professionals from across all areas of expertise to engage with patients, peers and thought leaders in a neutral environment on the issues of today and the possibilities for to...

This week, we have a conversation with congenital myotonic dystrophy patient advocacy consultant Lisa Harvey-Duren, who was the founding Myotonic Dystrophy Foundation executive director in 2008, and Michael Snape, CEO and CSO of AMO Pharma, which is developing a treatment for the disease.

AMO Pharma

AMO Pharma is a clinical-stage specialty biopharmaceutical company working to identify and advance promising therapies for the treatment...

This week, our conversations are with Uwe Diegel, CEO of Lifeina, about their cooling technologies, and with Dirk Beher, CEO of FundaMental Pharma, about treatment resistant depression.

Times:

02:37 FundaMental Pharma

23:56 Lifeina

FundaMental

FundaMental Pharma is a preclinical biopharmaceutical company focused on developing new treatments for treatment‑resistant depression (TRD).

The company’s platform centres on proprietary dual...

This week, our conversations are with Bruce Leuchter, co-founder, president, CEO of Neurvati Neurosciences and GRIN Therapeutics; and Daniel Vitt, CEO of Immunic.

Times:

02:54 Immunic

24:04 Neurvati Neurosciences/GRIN Therapeutics

GRIN Therapeutics

GRIN Therapeutics Inc. is dedicated to the research and development of precision therapeutics for neurodevelopmental disorders with the goal of bringing hope to patients and caregivers.

In 202...

This week, our conversations are with Steve Perrin, president and CSO of Eledon Pharmaceuticals, and Jason Bock, CEO and co-founder of CTMC.

Times:

03:18 CTMC

35:46 Eledon Pharmaceuticals

CTMC

CTMC is a joint venture between Resilience and the MD Anderson Cancer Center. It works like an internal manufacturing group, adapting to change in real time without charge ups and allowing for better control as a company develops their research pr...

This week, because April 11 is World Parkinson’s Day, we chat with Dieter Willbold, CSO of Priavoid, and Antje Willuweit, director preclinical development of Priavoid, and Karsten Eastman, CEO and co-founder of Sethera Therapeutics, about the company’s work on peptides.

Times:

02:52 Sethera Therapeutics

22:35 Priavoid

Priavoid

Priavoid, a company advancing novel disease-modifying approaches for neurodegenerative disorders, r...

On this week’s episode, as April 2 is World Autism Day, we have a conversation with Manish Arora, CEO of LinusBio, on its test that can rule out if someone has autism, and we talk to Thomas Kledal, CEO of Synklino, about improving kidney transplantation outcomes through better cytomegalovirus (CMV) prevention.

Times:

03:18 LinusBio

35:43 Synklino

LinusBio

LinusBio has expanded access to its ClearStrand ASD test, the first non-inva...

On this week’s episode, we chat with Hans Eriksson, chief medical officer (CMO) of HMNC Brain Health, about ketamine and treatment-resistant depression, and with Krishna Polu, CEO, president and co-founder of new kidney health biotech company R1 Therapeutics.

Times:

03:57 HMNC Brain Health

29:47 R1 Therapeutics

HMNC Brain Health

HMNC Brain Health is a Munich-based clinical-stage biopharma company developing personalised treatments...